Background. The aim of this study was to evaluate the effect of chronic hepatitis B infection on the risk of synchronous colorectal liver metastasis (synCRLM).
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females worldwide [1, 2] . Notably, the incidence of CRC is increasing rapidly in some areas, such as China where the incidence has historically been low. In 2015, there were 376 300 estimated new cases of CRC in China [3] . The mortality rates of CRC in China have also risen markedly from 46.0 to 72.5 per 100 000 population from the mid-1970s to the present. This increase is particularly evident in large cities, such as Shanghai, where the incidence increased from 60.9 and 57.0 per 100 000 population to 147.0 and 143. 5 per 100 000 population in men and women, respectively [4] .
Distant metastasis is one of the strongest independent prognostic factors of 5-year survival rate in CRC. The liver is the most common site for metastasis of CRC and is frequently the only organ involved. Previous studies have demonstrated that 14%-25% of CRC patients present with synchronous colorectal liver metastasis (synCRLM) when the primary tumor is diagnosed [5] [6] [7] [8] [9] , and 20%-33% of CRC patients develop metachronous liver metastases after treatment of the primary tumor [5, 6] . Chronic hepatitis B (CHB) is highly prevalent in China, and the prevalence of hepatitis B virus (HBV) infection is the highest of all countries globally [10, 11] . The prevalence of hepatitis B surface antigen (HBsAg) positivity in China was 8.8% in 1979, 9.8% in 1992, and 7.2% in 2006 [12] [13] [14] [15] .
With the high prevalence of hepatitis B and the increasing incidence of CRC in a large population such as China, we sought to explore the impact of HBV on the risk of liver metastases. Thus far, several studies have reported that HBV infection reduced the risk of CRLM [16] [17] [18] [19] . However, these studies had varying definitions and methodologic issues that rendered their conclusions somewhat debatable. Updated studies that investigate the mechanisms underlying the effects of HBV infection on CRC liver metastasis are clearly needed. Determining the effect of concomitant HBV infection on the risk of CRLM is of particular significance among the Chinese population. In this large-scale, retrospective clinical study from 4033 consecutive cases of newly diagnosed CRC with detailed HBV information, we obtained unique but interesting results.
METHODS
This is a retrospective, cross-sectional study of all consecutive patients with newly diagnosed CRC who presented to 2 hospitals (the Shandong Cancer Hospital and the Affiliated Hospital of Qingdao University) between January 2010 and January 2016. All patients had undergone laboratory examinations, which included HBV serologies. The study was approved by the Ethics Committee of Shandong Cancer Hospital and Institute and the Ethics Committee of the Affiliated Hospital of Qingdao University.
All patients had pathological confirmation of their colorectal cancer. The cohort included patients who underwent colorectal resection and in these patients, tumor characteristics were based on both imaging and pathology reports from the surgical procedure. Additionally, patients were included if the diagnosis of colorectal cancer was made with a colonoscopy and biopsy but if they were not surgical candidates because of widely spread metastases, medical comorbidities, or the decision to pursue neoadjuvant chemotherapy prior to any surgical intervention.
Data collected included demographic information (age, gender) and laboratory studies, including the following: HBsAg, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (GGT), platelet count, and the following tumor markers: carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). Fibrosis-4 Index for Liver Fibrosis (FIB-4) and AST-to-platelet ratio index (APRI) were calculated and used as the indicators of liver fibrosis/cirrhosis. Tumor characteristics, including tumor size, differentiation (well, moderate, or poor), and tumor (T) and nodal (N) stage, based on the American Joint Committee on Cancer staging, were also noted based on pathology reports.
All patients underwent chest, abdominal, and pelvic imaging prior to surgery. Initially, patients had abdominal and pelvic ultrasonography and chest radiography; when hepatic and/or pulmonary lesion(s) could not be excluded, patients underwent a computed tomography (CT) scan. All diagnoses of liver and lung metastases were independently confirmed by CT scan by 2 senior radiologists. SynCRLM was defined as the simultaneous diagnosis of liver metastasis together with primary CRC.
Patients were divided into 2 cohorts depending on the presence of hepatitis B (HBsAg + vs HBsAg -). The prevalence of synCRLM and baseline clinicopathological parameters were compared between HBsAg + and HBsAg -patients; significant predictors for synCRLM were analyzed by univariate and multivariate logistic regression analysis; FIB-4, APRI, and hepatitis B e antigen (HBeAg) status was compared between patients with or without synCRLM.
Statistical Analysis
The prevalence of synCRLM in different groups was compared by χ 2 test. Baseline categorical clinical parameters were compared by χ 2 test, and numerical values were compared using Student t test. FIB-4 and APRI were compared by Wilcoxon rank-sum test. Significant risk factors for synCRLM were analyzed first by univariate logistic regression analysis and then by multivariate logistic regression analysis. Statistical analysis was performed using SPSS version 17.0 software.
RESULTS
During the 6-year study period, 4033 patients with CRC and known HBV status were identified in the 2 hospitals and included in this study. Among all subjects, 244 (6.05%) patients were HBsAg positive (HBsAg + cohort) and 3789 (93.95%) patients were HBsAg negative (HBsAg -cohort). Baseline clinicopathological parameters of the 2 cohorts are presented in Table 1 . The mean age of the HBsAg + patients was significantly lower than that of the HBsAg -patients (mean ± SD, 57.25 ± 10.76 vs 62.69 ± 11.97 years, respectively, P < .001).
There were no significant differences in gender distribution, tumor size, or stage. SynCRLM was confirmed in 364 patients, and the general prevalence of synCRLM was 9.03%. The prevalence of synCRLM was 15.57% in the HBsAg + cohort, which was significantly higher than the prevalence of 8.60% found in the HBsAg -cohort (P < .001, χ 2 test). In 326 patients with syn-CRLM but no HBsAg, 8 patients (2.45%) were first diagnosed with liver mass by ultrasound during an asymptomatic regular healthy examination; in 38 patients with synCRLM and HBsAg, only 1 patient (2.63%) was first diagnosed with a liver mass by ultrasound during an asymptomatic regular healthy examination; there was no significant difference between the 2 cohorts (P = 1.000, χ 2 test) (Supplementary Table 1 ). Following univariate logistic regression analysis, platelet count, total bilirubin, CEA, CA19-9, ALT, AST, GGT, alkaline phosphatase, tumor stage, lymph node metastasis, and positive HBsAg were chosen (Supplementary Table 2 ) for the subsequent multivariate logistic regression analysis, which finally indicated that CEA, CA19-9, ALT, AST, GGT, tumor stage, and positive HBsAg were significant predictors for synCRLM and that HBsAg positivity had the highest hazard ratio (2.317 [95% confidence interval, 1.406-3.820]; Table 2 ). Synchronous lung metastasis was found in 115 patients, with an overall prevalence of 2.85%. The prevalence of lung metastasis was 0.82% in the HBsAg + cohort, and it was significantly lower compared to the prevalence of 2.98% in the HBsAg -cohort (P = .049, χ 2 test; Table 3 ). Table 4 ).
DISCUSSION
Previous studies have reported the occurrence of synCRLM in 14%-25% of patients [5] [6] [7] [8] [9] . In our study, the overall prevalence of synCRLM was 9.03%. The decreased prevalence of synCRLM in our study may be related to inconsistencies in the definition of "synchronous" [20] . In this particular study, synchronous is defined as the simultaneous diagnosis of a primary CRC with liver metastasis at initial presentation. Other studies have defined synchronous as the development of a liver metastasis within 6 months and even up to 12 months after the primary lesion has been identified [20] . We believe that our current study of synCRLM prevalence reflects a population in the era of modern cancer education, screening, and early diagnosis and is likely more accurate than the general data from the prior literature. This study also demonstrated a higher prevalence of synCRLM in patients with positive HBsAg at 15.6% compared to a prevalence of 8.6% in those with negative HBsAg. Both American and Chinese guidelines for hepatocellular carcinoma (HCC) recommend ultrasound examination-based surveillance in patients with CHB [21, 22] . In the American Association for the Study of Liver Diseases practice guidelines, the recommended screening interval is 6 months [22] . To determine whether the increased prevalence of synCRLM may have merely been due to more frequent ultrasound Our results contrast with those in previous studies [23, 24] . However, previous reports have studied fairly heterogeneous populations of chronic liver disease that included alcoholic liver disease, nonalcoholic steatohepatitis, CHB, chronic hepatitis C (CHC), and traumatic liver injury. In a meta-analysis of 10 studies [25] , the authors finally concluded that patients with chronically diseased livers had significantly lower incidences of CRLM than those with normal livers. The types of liver diseases in this meta-analysis included fatty liver, hepatitis infection, cirrhosis, or any combination of these diseases, and both synchronous and metachronous CRLM were included.
Studies that have more specifically evaluated CRLM in the setting of chronic viral hepatitis have also demonstrated a decreased incidence of CRLM [16, 26, 27] . In a retrospective study by Li Destri et al [26] , the incidence of metachronous CRLM in patients without CHB or CHC was 9.4% compared to an incidence of 3.2% in patients with concomitant CHB or CHC. Wang et al [27] reported that the incidence of CRLM in patients with concomitant CHB or CHC was significantly lower at 2.86% compared with an incidence of 16.9% in those without CHB or CHC. In another study from China, Qiu et al [16] reported that the incidence of CRLM was significantly lower at 14.2%, compared with an incidence of 28.2% in the control group. Both of these studies were retrospective, and the authors did not distinguish between synchronous and metachronous metastasis. Notably, in another study from the same corresponding authors of Qiu et al's report, it was reported that the presence of CHB in patients with pancreatic carcinoma significantly increased the incidence of liver metastasis [28] , despite the fact that colorectal and pancreatic cancer both metastasize to the liver via the portal venous system.
To further study the synCRLM inside the HBsAg + cohort, FIB-4/APRI values and HBeAg positivity were compared between patients with and without synCRLM. Although APRI may only have moderate diagnostic efficacy for fibrosis/cirrhosis compared to that of a liver biopsy, APRI is noninvasive, inexpensive, and widely available, which would facilitate its use in a clinical setting [29] [30] [31] . The fibrosis-predicting efficacy of FIB-4 is similar to that of APRI but also takes age into consideration [31] . Both FIB-4 and APRI in patients with positive HBsAg but no synCRLM were significantly higher compared to FIB-4 and APRI in patients with positive HBsAg and synCRLM. HBeAg positivity in those with positive HBsAg but no synCRLM was lower (but not significantly) compared to HBeAg positivity in those with positive HBsAg and synCRLM. Therefore, one possible interpretation of the above findings might be that chronic HBV infection generally increases the risk of CRLM, whereas fibrosis/cirrhosis decreases it; further study is thus needed to determine whether active HBV replication is prometastatic. Indeed, most of the previous clinical studies support that cirrhosis reduces the risk of liver metastases [24] , while hepatitis B virus X protein facilitates the progression of liver metastases by different mechanisms in HCC [32] [33] [34] [35] [36] [37] [38] , and these prometastatic mechanisms are potentially applicable to CRLM as well. More directly, our previous in vivo study proved that CRLM foci support the growth of CRC via the chemokine and receptor pair monocyte chemoattractant protein 1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCR2) [39] , while CHB patients also have an increased peripheral MCP-1 level [40] . It is possible that such a mechanism may increase the risk of CRLM in patients with CHB.
This study is limited in that there was insufficient information on other factors that may influence the development of liver disease, including obesity, diabetes, and alcohol consumption, and that fibrosis/cirrhosis was measured by FIB-4/APRI and not by liver biopsy. Additionally, there was incomplete information on HBV DNA levels. We acknowledge that with our modalities (ultrasound and chest radiograph), there may be an inferior detection of very small metastases compared to that of CT, magnetic resonance imaging, or positron emission tomography. However, all patients in the study were subjected to the same imaging protocol, and while this may be suboptimal for detection, the rates and limits of detectability were consistent for all patients.
Despite these limitations, this study involved a large cohort of patients with CRC, who had clearly defined synchronous lesions, and all with information about the patients' hepatitis B status. This is the first study to explore the specific effects of hepatitis B fibrosis/cirrhosis on the development of synCRLM. Furthermore, this study provides a potential interpretation of the 2 aspects of HBV infection with the suggestion that fibrosis/cirrhosis may be antimetastatic, while active viral replication is likely prometastatic. An awareness of hepatitis B status and the extent of liver disease in patients may help physicians define the risk for development of CRLM and may ultimately influence the treatment of both CRC and CHB in select populations. Hopefully, the hypothesis generated in this study will prompt others to validate our findings with carefully designed prospective studies, ideally randomized controlled trials, that utilize dynamic imaging and liver biopsy as well as additional laboratory examinations and longer follow-up period to monitor the development of metachronous CRLM.
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